Position in TERN
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$0
+$0 QoQ
Shares Held
123,334
+16.1% QoQ
Ownership
0.107%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
12 quarters on record
Voting authority
Sole 18%
Shared 0%
None 82%
Common Shares in TERN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RHUMBLINE ADVISERS holds $1,404,721,264 across 329 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
396,380 | $196,893,837 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,794 | $98,390,870 | |
| 3 | MRNA |
Moderna, Inc.
|
809,853 | $56,714,005 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
165,579 | $49,844,246 | |
| 5 | INCY |
Incyte Corp
|
428,533 | $48,578,500 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
226,008 | $42,326,778 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
1,178,789 | $41,717,342 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
163,018 | $39,282,447 |
All Filings in TERN
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 123,334 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | — | 106,241 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | — | 104,837 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | — | 106,451 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | — | 96,659 | Shares | Sole | 2025-05-29 | |
| 2024-12-31 | — | 97,892 | Shares | Sole | 2025-05-29 | |
| 2024-09-30 | — | 84,413 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | — | 88,641 | Shares | Sole | 2024-08-01 | |
| 2024-03-31 | — | 58,982 | Shares | Sole | 2024-05-09 | |
| 2023-12-31 | — | 57,563 | Shares | Sole | 2024-02-08 | |
| 2023-09-30 | — | 59,129 | Shares | Sole | 2023-11-09 | |
| 2023-06-30 | — | 57,950 | Shares | Sole | 2023-08-08 | |
| No filing history on record for this holder in this stock. | ||||||